Article thumbnail

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

By L Stingl, T Stühmer, M Chatterjee, M R Jensen, M Flentje and C S Djuzenova
Topics: Translational Therapeutics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2883148
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168: 115–124 Zuco
  2. (2008). Cancer Inst 91: 1940–1949
  3. (1999). DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
  4. (2003). Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
  5. (2009). Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.